Simplifying and accelerating industry access to the NIHR clinical research infrastructure
NOCRI’s work to simplify access to the NIHR infrastructure is continuing to speed up industry engagement bringing drugs, devices and diagnostics to patients faster.
- 151 enquires were received by NOCRI by companies looking to explore collaborative opportunities
- 86 projects were active as a result of NOCRI supported activities.
Delivering industry collaborative research for the NIHR infrastructure
NOCRI-developed partnerships and collaborations continue to provide the life sciences industry access to the NIHR’s world-class expertise and capabilities, driving innovation in key areas and attracting global investment to the UK.
NOCRI was instrumental in establishing and promoting the NIHR Rare Diseases Translational Research Collaboration call for industry collaborative research. This resulted in 29 expressions of interest and 9 active projects co-funded by NIHR and industry partners, leveraging more than £1.3 million investment from industry.
NOCRI also leveraged £2.5 million funding for the NIHR Diagnostic Evidence Co-operatives by working closely with Innovate UK to shape its Stratified Medicine SBRI call. NOCRI’s involvement resulted in:
- 10 out of the 12 successfully funded applications having NIHR DEC involvement
- 1/3 of the successful applicants having industry/academia partnerships established through NOCRI.
Helping charities to understand NIHR and the opportunities for working together
NOCRI continues to work with medical research charities to increase awareness of the NIHR and to identify opportunities for joint working.
Cancer Research UK, World Cancer Research Fund and the National Cancer Research Institute are all active participants in the Cancer & Nutrition NIHR infrastructure collaboration, which aims to improve the nutritional care and advice that cancer patients receive by bringing coherence to existing activities in nutrition and cancer.
NOCRI collaborated with Arthritis UK on the Arthritis Research UK call for industry collaborative clinical studies to accelerate new treatments for rheumatic diseases. This resulted in a Lupus study co-funded by Arthritis Research UK and GSK.